Ras-associated autoimmune lymphoproliferative disorder
- PMID: 38797558
- DOI: 10.1111/bjh.19564
Ras-associated autoimmune lymphoproliferative disorder
Abstract
Distinguishing RALD from JMML can be difficult. This review discusses the clinical features, genetic aetiology and the treatments that are common and distinct between the two diagnoses.
Keywords: autoimmune disease; leukaemia; myeloid leukaemia; spleen.
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
References
REFERENCES
-
- Riller Q, Rieux‐Laucat F. RASopathies: from germline mutations to somatic and multigenic diseases. Biom J. 2021;44(4):422–432.
-
- Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O, et al. Juvenile myelomonocytic leukaemia and Noonan syndrome. J Med Genet. 2014;51(10):689–697.
-
- Siano MA, Marchetti V, Pagano S, Di Candia F, Alessio M, De Brasi D, et al. Risk of autoimmune diseases in patients with RASopathies: systematic study of humoral and cellular immunity. Orphanet J Rare Dis. 2021;16(1):410.
-
- Neven Q, Boulanger C, Bruwier A, de Ville de Goyet M, Meyts I, Moens L, et al. Clinical spectrum of Ras‐associated autoimmune leukoproliferative disorder (RALD). J Clin Immunol. 2021;41(1):51–58.
-
- Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126(4):746–759.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
